

# Marc-Eric Halatsch

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5736819/publications.pdf>

Version: 2024-02-01

29  
papers

923  
citations

471371

17  
h-index

477173

29  
g-index

29  
all docs

29  
docs citations

29  
times ranked

1608  
citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | A conceptually new treatment approach for relapsed glioblastoma: Coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care. <i>Oncotarget</i> , 2013, 4, 502-530. | 0.8 | 152       |
| 2  | CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide. <i>Oncotarget</i> , 2014, 5, 8052-8082.                   | 0.8 | 99        |
| 3  | Combined Inhibition of HER1/EGFR and RAC1 Results in a Synergistic Antiproliferative Effect on Established and Primary Cultured Human Glioblastoma Cells. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 1783-1795.   | 1.9 | 50        |
| 4  | Matrix Metalloproteinase-2 and -9 in Glioblastoma: A Trio of Old Drugs—Captopril, Disulfiram and Nelfinavir—Are Inhibitors with Potential as Adjunctive Treatments in Glioblastoma. <i>Archives of Medical Research</i> , 2012, 43, 243-247.                          | 1.5 | 47        |
| 5  | Metabolic reprogramming of glioblastoma cells by L-asparaginase sensitizes for apoptosis in vitro and in vivo. <i>Oncotarget</i> , 2016, 7, 33512-33528.  | 0.8 | 47        |
| 6  | Glioblastoma-synthesized G-CSF and GM-CSF contribute to growth and immunosuppression: Potential therapeutic benefit from dapsone, fenofibrate, and ribavirin. <i>Tumor Biology</i> , 2017, 39, 101042831769979.   | 0.8 | 45        |
| 7  | Combined inhibition of Bcl-2/Bcl-xL and Usp9X/Bag3 overcomes apoptotic resistance in glioblastoma <i>in vitro</i> and <i>in vivo</i> . <i>Oncotarget</i> , 2015, 6, 14507-14521.  | 0.8 | 45        |
| 8  | RIST: A potent new combination therapy for glioblastoma. <i>International Journal of Cancer</i> , 2015, 136, E173-87.   | 2.3 | 42        |
| 9  | A paired comparison between glioblastoma stem cells and differentiated cells. <i>International Journal of Cancer</i> , 2016, 138, 1709-1718.  | 2.3 | 42        |
| 10 | PARP Inhibition Restores Extrinsic Apoptotic Sensitivity in Glioblastoma. <i>PLoS ONE</i> , 2014, 9, e114583.   | 1.1 | 38        |
| 11 | A Potential Role for the Inhibition of PI3K Signaling in Glioblastoma Therapy. <i>PLoS ONE</i> , 2015, 10, e0131670.  | 1.1 | 37        |
| 12 | Cancer stem cells: The potential role of autophagy, proteolysis, and cathepsins in glioblastoma stem cells. <i>Tumor Biology</i> , 2017, 39, 101042831769222.   | 0.8 | 36        |
| 13 | Inhibition of deubiquitinases primes glioblastoma cells to apoptosis <i>in vitro</i> and <i>in vivo</i> . <i>Oncotarget</i> , 2016, 7, 12791-12805.   | 0.8 | 35        |
| 14 | Artesunate Enhances the Antiproliferative Effect of Temozolomide on U87MG and A172 Glioblastoma Cell Lines. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2014, 14, 313-318.   | 0.9 | 35        |
| 15 | Anti-glioma Activity of Dapsone and Its Enhancement by Synthetic Chemical Modification. <i>Neurochemical Research</i> , 2017, 42, 3382-3389.  | 1.6 | 29        |
| 16 | Blocking epithelial-to-mesenchymal transition in glioblastoma with a sextet of repurposed drugs: the EIS regimen. <i>Oncotarget</i> , 2017, 8, 60727-60749.   | 0.8 | 27        |
| 17 | A phase Ib/IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma: CUSP9v3. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab075.  | 0.4 | 26        |
| 18 | Blocking distinct interactions between Glioblastoma cells and their tissue microenvironment: A novel multi-targeted therapeutic approach. <i>Scientific Reports</i> , 2018, 8, 5527.  | 1.6 | 15        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Augmentation of 5-Aminolevulinic Acid Treatment of Glioblastoma by Adding Ciprofloxacin, Deferiprone, 5-Fluorouracil and Febuxostat: The CAALA Regimen. <i>Brain Sciences</i> , 2018, 8, 203.   | 1.1 | 15        |
| 20 | Combined inhibition of RAC1 and Bcl-2/Bcl-xL synergistically induces glioblastoma cell death through down-regulation of the Usp9X/Mcl-1 axis. <i>Cellular Oncology (Dordrecht)</i> , 2019, 42, 287-301.                                       | 2.1 | 13        |
| 21 | The ABC7 regimen: a new approach to metastatic breast cancer using seven common drugs to inhibit epithelial-to-mesenchymal transition and augment capecitabine efficacy. <i>Breast Cancer: Targets and Therapy</i> , 2017, Volume 9, 495-514. | 1.0 | 10        |
| 22 | Photodynamic Therapy Combined with Bcl-2/Bcl-xL Inhibition Increases the Noxa/Mcl-1 Ratio Independent of Usp9X and Synergistically Enhances Apoptosis in Glioblastoma. <i>Cancers</i> , 2021, 13, 4123.                                       | 1.7 | 9         |
| 23 | In Vitro and Clinical Compassionate Use Experiences with the Drug-Repurposing Approach CUSP9v3 in Glioblastoma. <i>Pharmaceuticals</i> , 2021, 14, 1241.  | 1.7 | 8         |
| 24 | A New Treatment Opportunity for DIPG and Diffuse Midline Gliomas: 5-ALA Augmented Irradiation, the 5aai Regimen. <i>Brain Sciences</i> , 2020, 10, 51.  | 1.1 | 7         |
| 25 | MDACT: A New Principle of Adjunctive Cancer Treatment Using Combinations of Multiple Repurposed Drugs, with an Example Regimen. <i>Cancers</i> , 2022, 14, 2563.  | 1.7 | 7         |
| 26 | ACTR-44. PRELIMINARY RESULTS FROM THE NCT02770378 PROOF-OF-CONCEPT CLINICAL TRIAL ASSESSING THE SAFETY OF THE CUSP9v3 PROTOCOL COMBINED WITH METRONOMIC TEMOZOLOMIDE FOR RECURRENT GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, vi21-vi21. | 0.6 | 2         |
| 27 | Rare Case of Sporadic Malignant Optic Pathway Glioma in 71-Year-Old Woman. <i>World Neurosurgery</i> , 2020, 133, 413-415.  | 0.7 | 2         |
| 28 | OPALS: A New Osimertinib Adjunctive Treatment of Lung Adenocarcinoma or Glioblastoma Using Five Repurposed Drugs. <i>Cells</i> , 2021, 10, 1148.  | 1.8 | 2         |
| 29 | CTNI-04. RECURRENT GLIOBLASTOMA LONG-TERM SURVIVORS TREATED WITH CUSP9v3. <i>Neuro-Oncology</i> , 2021, 23, vi59-vi59.  | 0.6 | 1         |